Moleculin Biotech, Inc. (MBRX) Income Statement
MBRX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsMBRX revenue and net income
MBRX profit margins
MBRX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
MBRX quarterly EPS vs estimates
Moleculin Biotech beat the analyst EPS estimate in 4 of the last 8 quarters. Next report: November 12, 2026 (estimate $-0.50).
MBRX income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $9,000 | $0 |
| Cost of revenue | $90,000 | $126,000 | $127,000 | $222,000 | $260,000 | $285,000 | $185,000 | $68,000 | $18,000 | $6,162 |
| Gross profit | −$90,000 | −$126,000 | −$127,000 | −$222,000 | −$260,000 | −$285,000 | −$185,000 | −$68,000 | −$18,000 | −$6,162 |
| Research & development | $15.9M | $17.7M | $19.5M | $19.0M | $14.4M | $12.8M | $11.0M | $9.7M | $4.5M | $1.5M |
| Sales, general & admin | $9.1M | $8.8M | $10.0M | $11.5M | $8.4M | $6.8M | $6.3M | $5.3M | $4.1M | $2.4M |
| Total operating expenses | $25.1M | $26.6M | $29.6M | $30.6M | $23.0M | $19.7M | $17.3M | $15.0M | $8.7M | $3.9M |
| Operating income | −$25.1M | −$26.6M | −$29.6M | −$30.6M | −$23.0M | −$19.7M | −$17.5M | −$15.0M | −$8.7M | −$3.9M |
| Interest income | $105,000 | $550,000 | $1.2M | $240,000 | $306,000 | $13,000 | $4.1M | $3.2M | $1.3M | $43,210 |
| Interest expense | — | — | — | $1.6M | $7.1M | $13,000 | $8.2M | $0 | $0 | $43,214 |
| Income before taxes | −$33.6M | −$21.8M | −$29.8M | −$29.0M | −$15.9M | −$17.4M | −$13.4M | −$11.9M | −$9.8M | −$3.9M |
| Income taxes | — | — | — | −$1.6M | −$7.0M | −$2.4M | −$229,000 | $3.1M | $1.2M | $0 |
| Net income | −$33.6M | −$21.8M | −$29.8M | −$29.0M | −$15.9M | −$17.4M | −$13.2M | −$11.9M | −$9.8M | −$3.9M |
| EBITDA | −$33.5M | −$21.6M | −$29.6M | −$28.9M | −$15.7M | −$19.5M | −$13.2M | −$15.0M | −$8.6M | −$3.9M |
| EPS (diluted) | −$25.35 | −$164.81 | −$255.97 | −$299.55 | −$225.99 | −$642.25 | −$719.13 | −$1109.25 | −$2.21 | −$2.69 |
| Gross margin | — | — | — | — | — | — | — | — | −200.0% | — |
| Operating margin | — | — | — | — | — | — | — | — | −96,144.4% | — |
| Net margin | — | — | — | — | — | — | — | — | −108,944.4% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $63,000 | $126,000 | $0 | $0 | $406,000 | $406,000 | $0 |
| Cost of revenue | — | $8,000 | $9,000 | $21,000 | $29,000 | $31,000 | $31,000 | $31,000 | $31,000 | $32,000 | $35,000 | $32,000 |
| Gross profit | — | −$8,000 | −$9,000 | −$21,000 | −$29,000 | −$31,000 | −$31,000 | −$31,000 | −$31,000 | −$32,000 | −$35,000 | −$32,000 |
| Research & development | $5.5M | $5.4M | $5.1M | $3.7M | $3.6M | $3.4M | $4.5M | $4.9M | $4.1M | $4.3M | $6.6M | $3.3M |
| Sales, general & admin | $2.1M | $2.5M | $2.4M | $2.1M | $2.1M | $2.5M | $2.2M | $2.2M | $2.1M | $2.4M | $2.3M | $2.6M |
| Total operating expenses | $7.6M | $7.9M | $7.5M | $5.9M | $5.7M | $5.9M | $6.6M | $7.1M | $6.2M | $6.7M | $8.9M | $5.9M |
| Operating income | −$7.6M | −$7.9M | −$7.5M | −$5.9M | −$5.7M | −$5.9M | −$6.6M | −$7.1M | −$6.2M | −$6.7M | −$8.9M | −$5.9M |
| Interest income | — | $34,000 | $9,000 | $39,000 | $26,000 | $30,000 | $47,000 | $102,000 | $159,000 | $241,000 | $262,000 | $324,000 |
| Interest expense | $78,000 | — | — | — | — | — | — | — | — | $439,000 | $439,000 | — |
| Income before taxes | −$7.6M | −$12.8M | $15.6M | −$25.4M | −$7.6M | −$6.4M | −$1.9M | −$10.6M | −$4.3M | −$5.0M | −$10.3M | −$5.6M |
| Income taxes | — | — | — | — | — | — | — | — | — | $965,000 | $965,000 | $71,586 |
| Net income | −$7.6M | −$12.8M | $15.6M | −$25.4M | −$7.6M | −$6.4M | −$1.9M | −$10.6M | −$4.3M | −$5.0M | −$10.3M | −$5.6M |
| EBITDA | −$7.6M | −$12.8M | $15.6M | −$25.4M | −$7.6M | −$6.4M | −$1.9M | −$10.6M | −$4.3M | −$4.9M | −$10.2M | −$5.6M |
| EPS (diluted) | −$1.40 | −$3.54 | $4.83 | −$0.68 | −$12.25 | −$17.25 | −$0.56 | −$71.25 | −$42.50 | −$50.50 | −$5.02 | −$71.25 |
| Gross margin | — | — | — | — | — | −49.2% | −24.6% | — | — | −7.9% | −8.6% | — |
| Operating margin | — | — | — | — | — | −9,433.3% | −5,272.2% | — | — | −1,644.6% | −2,196.8% | — |
| Net margin | — | — | — | — | — | −10,215.9% | −1,493.7% | — | — | −1,224.1% | −2,529.3% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in MBRX's financial statements (latest annual report filed March 18, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
MBRX financial results
Moleculin Biotech reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $33.6 million. Diluted earnings per share came to −$25.35.
See the MBRX stock overview for the latest quote and news, or the MBRX chart for price history and technical indicators.
MBRX income statement FAQ
Does Moleculin Biotech have revenue?
Moleculin Biotech reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Moleculin Biotech profitable?
No. Moleculin Biotech reported a net loss of $33.6 million in fiscal 2025.
How much does Moleculin Biotech spend on research and development?
Moleculin Biotech spent $15.9 million on research and development in fiscal 2025.
What are Moleculin Biotech's earnings per share?
Moleculin Biotech earned $-25.35 per diluted share in fiscal 2025, compared with $-164.81 a year earlier.
When will Moleculin Biotech report its next earnings?
Moleculin Biotech is expected to report results for the quarter ending September 30, 2026 on November 12, 2026.
When does Moleculin Biotech's fiscal year end?
Moleculin Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 18, 2026.